Revised Recommendations for the Treatment of Tuberculosis Disease
Revised national recommendations These guidelines, which replace Following are some highlights of the for the treatment of tuberculosis (TB) previous recommendations published new guidelines: disease were recently issued by the in 1994, were developed to address Centers for Disease Control and current issues such as the availability 1. The responsibility for successPrevention (CDC), the Infectious of new antituberculosis drugs and ful completion of an appropriate Diseases Society of America (IDSA), recent research findings on treatment TB treatment regimen is clearly and the American Thoracic Society regimens. The new recommendaassigned to the private clinician (ATS). This is the first time IDSA has tions provide updated information and public health department, co-authored a TB treatment stateand guidance on several issues of rather than to the patient. ment with ATS and CDC. The particular interest to clinicians who guidelines, "Treatment of Tuberculocare for TB patients in Minnesota. This is a significant philosophic sis," were published in the American These issues include drug-resistant departure from previous guide-
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TB and extrapulmonary diseaselines. Successful treatment of TB Care Medicine (2003; 167:603-662) both of which occur most frequently benefits both the individual patient and reprinted in Morbidity and among foreign-born TB patients, who and the larger community by Mortality Weekly Report (MMWR comprise (Table 2) .
response to therapy is esseneffects make it impossible to tial; this includes obtaining administer the recommended Each regimen consists of an sputum cultures upon complenumber of doses within the initial phase of 2 months tion of the initial 2-month phase specific period of time, the length followed by the choice of several of treatment (Figure 1 ). of treatment may be extended to options for a continuation phase allow for administration of the total of 4 to 7 months. Regimens are
Patients with cavitary disease and number of recommended doses rated according to their effecwhose sputum culture has not (Table 2) . For example, if the 6 tiveness and the strength of converted to negative for Mycomonth regimen must be extended, scientific evidence supporting bacterium tuberculosis following the number of doses recom their use. Due to the high the initial 2-month phase of mended for the initial 2-month prevalence of isoniazid-resistant therapy are at increased risk for phase of treatment should be TB, the initial regimen for most relapse. Such patients who administered within 3 months and adults should include four drugs.
initially were started on a 6-month the recommended number of The guidelines describe the regimen (i.e., 2 month initial doses for the 4-month continuaprinciples of antituberculosis phase followed by a 4 month tion phase should be administered therapy and contain detailed continuation phase) require a within 6 months, so that the usual drug-specific information about continuation phase of 7 months, 6-month regimen is completed first-and second-line medicafor a total of 9 months of treatwithin 9 months. If the recom tions (Table 3) 
Time (months)
Abbreviations: TB = tuberculosis, INH = isoniazid, RIF = rifampin, EMB = ethambutol, PZA = pyrazinamide, RPT = rifapentine, CXR = chest radiograph, AFB = acid-fast bacillus *EMB may be discontinued when drug susceptibility results indicate no drug resistance. † PZA may be discontinued after it has been taken for 2 months (56 doses). ‡ RPT should not be used in HIV-infected patients or in patients with extrapulmonary TB. § Therapy should be extended to 9 months if culture is positive after 2 months of initial phase of treatment. Most of the increase in breast cancer in Minnesota has occurred among women 50 to 64 years of age, for whom the incidence rate increased 34% from 1988 to 2000 (Figure 2 ). In contrast, the breast cancer incidence rate decreased slightly or remained stable among women less than 50 years of age and among women 65 years of age or older. SEER data demonstrate a similar trend nationally.
It appears that the risk of developing post-menopausal breast cancer is higher among women born after World War II, (i.e., "baby-boomers") than among the cohort of their mothers. This finding likely is due to a combination of factors. For example, this younger cohort of women delayed having children, had fewer children, and were more likely not to have children than their mothers. Because the nutritional status of the younger cohort of women was better, their menstruation likely began, on average, at an earlier age. Each of these character istics is a risk factor for breast cancer. Also, the use of combination hormone replacement therapy, which has been used widely among this younger generation of women, recently has been shown to significantly increase risk for breast cancer. 
Cancer Is the New Leading Cause of Death in Minnesota as Deaths From Heart Disease Decrease
For the first time in 2000 and again in 2001, more Minnesotans died of cancer than of heart disease, making cancer the leading cause of death in Minnesota. Cancer accounted for 24% of all deaths in Minnesota in 2001, compared to the 23% of deaths attributed to heart disease. Nationally, heart disease remained the leading cause of death, accounting for 29% percent of all deaths in 2001 (Table 1) .
Cancer has become the leading cause of death in Minnesota primarily because the heart disease mortality rate decreased by 40% from 1988 to 2000, while cancer mortality decreased by only 4% (Figure 1 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 
